Baidu
map

消化

订阅

MedSci主页 / 所有栏目 / 消化

Gut：家族性胰腺癌高危个体可50岁启动MRI联合EUS筛查

2016-06-04 高晓方 翻译 中国医学论坛报

胰腺癌MRI
关注

欧洲一项研究表明，在非CDKN2A基因突变的家族性胰腺癌(FPC)高危个体中，50岁启动胰腺导管腺癌筛查具安全性;MRI辅以超声内镜(EUS，基线时、每3年1次或MRI提示病变变化时)的筛查具有效性。论文5月24日在线发表于《消化道》(Gut)杂志。该研究纳入253例中位年龄48岁、非CDKN2A基因突变的FPC高危个体，给予MRI和EUS筛查。中位随访28个月。分析年龄和不同筛查方案的病变检出率

欧洲一项研究表明，在非CDKN2A基因突变的家族性胰腺癌(FPC)高危个体中，50岁启动胰腺导管腺癌筛查具安全性;MRI辅以超声内镜(EUS，基线时、每3年1次或MRI提示病变变化时)的筛查具有效性。论文5月24日在线发表于《消化道》(Gut)杂志。

该研究纳入253例中位年龄48岁、非CDKN2A基因突变的FPC高危个体，给予MRI和EUS筛查。中位随访28个月。分析年龄和不同筛查方案的病变检出率。

结果显示，中位筛查3次。基线或筛查中发现影像学胰腺病变为134例(53%)，主要为胰腺囊肿(94%)。年龄≥45岁的受试者胰腺病变检出率显著升高。21例接受手术的受试者中，在50岁前检出了非显著性病变。在50岁后受试者潜在相关性病变的发生率显著升高。每年MRI联合EUS或每年MRI联合每3年1次EUS筛查在潜在相关性病变检出率方面无显著差异，且在筛查间期12个月和≥24个月的病变检出率亦无显著差异。


原始出处：

Bartsch DK, Slater EP, Carrato A, Ibrahim IS, Guillen-Ponce C, Vasen HF, Matthäi E, Earl J, Jendryschek FS, Figiel J, Steinkamp M, Ramaswamy A, Vázquez-Sequeiros E, Muñoz-Beltran M, Montans J, Mocci E, Bonsing BA, Wasser M, Klöppel G, Langer P, Fendrich V, Gress TM. Refinement of screening for familial pancreatic cancer. Gut. 2016 May 24. pii: gutjnl-2015-311098. doi: 10.1136/gutjnl-2015-311098

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2016836, encodeId=e0442016836a4, content=<a href='/topic/show?id=8905e093b1' target=_blank style='color:#2F92EE;'>#EUS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7093, encryptionId=8905e093b1, topicName=EUS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b70c362, createdName=jiadan198782, createdTime=Sat Dec 10 18:15:00 CST 2016, time=2016-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629483, encodeId=5979162948389, content=<a href='/topic/show?id=c61d4641821' target=_blank style='color:#2F92EE;'>#家族性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46418, encryptionId=c61d4641821, topicName=家族性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26fc21339997, createdName=wetgdt, createdTime=Mon Jun 06 04:15:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88644, encodeId=746288644c6, content=不错的文章，多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sun Jun 05 21:14:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88518, encodeId=032988518f9, content=不错的文章，多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sun Jun 05 14:48:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88515, encodeId=099388515f2, content=不错的文章，多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sun Jun 05 14:47:00 CST 2016, time=2016-06-05, status=1, ipAttribution=)]
    2016-12-10 jiadan198782

    #EUS#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2016836, encodeId=e0442016836a4, content=<a href='/topic/show?id=8905e093b1' target=_blank style='color:#2F92EE;'>#EUS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7093, encryptionId=8905e093b1, topicName=EUS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b70c362, createdName=jiadan198782, createdTime=Sat Dec 10 18:15:00 CST 2016, time=2016-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629483, encodeId=5979162948389, content=<a href='/topic/show?id=c61d4641821' target=_blank style='color:#2F92EE;'>#家族性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46418, encryptionId=c61d4641821, topicName=家族性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26fc21339997, createdName=wetgdt, createdTime=Mon Jun 06 04:15:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88644, encodeId=746288644c6, content=不错的文章，多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sun Jun 05 21:14:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88518, encodeId=032988518f9, content=不错的文章，多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sun Jun 05 14:48:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88515, encodeId=099388515f2, content=不错的文章，多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sun Jun 05 14:47:00 CST 2016, time=2016-06-05, status=1, ipAttribution=)]
    2016-06-06 wetgdt

    #家族性#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2016836, encodeId=e0442016836a4, content=<a href='/topic/show?id=8905e093b1' target=_blank style='color:#2F92EE;'>#EUS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7093, encryptionId=8905e093b1, topicName=EUS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b70c362, createdName=jiadan198782, createdTime=Sat Dec 10 18:15:00 CST 2016, time=2016-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629483, encodeId=5979162948389, content=<a href='/topic/show?id=c61d4641821' target=_blank style='color:#2F92EE;'>#家族性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46418, encryptionId=c61d4641821, topicName=家族性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26fc21339997, createdName=wetgdt, createdTime=Mon Jun 06 04:15:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88644, encodeId=746288644c6, content=不错的文章，多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sun Jun 05 21:14:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88518, encodeId=032988518f9, content=不错的文章，多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sun Jun 05 14:48:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88515, encodeId=099388515f2, content=不错的文章，多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sun Jun 05 14:47:00 CST 2016, time=2016-06-05, status=1, ipAttribution=)]
    2016-06-05 沉心多思

    不错的文章，多学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2016836, encodeId=e0442016836a4, content=<a href='/topic/show?id=8905e093b1' target=_blank style='color:#2F92EE;'>#EUS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7093, encryptionId=8905e093b1, topicName=EUS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b70c362, createdName=jiadan198782, createdTime=Sat Dec 10 18:15:00 CST 2016, time=2016-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629483, encodeId=5979162948389, content=<a href='/topic/show?id=c61d4641821' target=_blank style='color:#2F92EE;'>#家族性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46418, encryptionId=c61d4641821, topicName=家族性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26fc21339997, createdName=wetgdt, createdTime=Mon Jun 06 04:15:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88644, encodeId=746288644c6, content=不错的文章，多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sun Jun 05 21:14:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88518, encodeId=032988518f9, content=不错的文章，多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sun Jun 05 14:48:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88515, encodeId=099388515f2, content=不错的文章，多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sun Jun 05 14:47:00 CST 2016, time=2016-06-05, status=1, ipAttribution=)]
    2016-06-05 沉心多思

    不错的文章，多学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2016836, encodeId=e0442016836a4, content=<a href='/topic/show?id=8905e093b1' target=_blank style='color:#2F92EE;'>#EUS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7093, encryptionId=8905e093b1, topicName=EUS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b70c362, createdName=jiadan198782, createdTime=Sat Dec 10 18:15:00 CST 2016, time=2016-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629483, encodeId=5979162948389, content=<a href='/topic/show?id=c61d4641821' target=_blank style='color:#2F92EE;'>#家族性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46418, encryptionId=c61d4641821, topicName=家族性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26fc21339997, createdName=wetgdt, createdTime=Mon Jun 06 04:15:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88644, encodeId=746288644c6, content=不错的文章，多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sun Jun 05 21:14:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88518, encodeId=032988518f9, content=不错的文章，多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sun Jun 05 14:48:00 CST 2016, time=2016-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88515, encodeId=099388515f2, content=不错的文章，多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sun Jun 05 14:47:00 CST 2016, time=2016-06-05, status=1, ipAttribution=)]
    2016-06-05 沉心多思

    不错的文章，多学习

    0

相关资讯

全球首例：中山医院成功完成“CT导引下胰腺射频消融导管治疗胰腺癌”

5月10日下午，中山医院介入科专家成功完成全球首例“CT导引下胰腺射频消融导管治疗胰腺癌”。在王小林教授的指导下，陈颐副主任医师带领杨敏捷、高珊珊医师，借助CT精确定位，将直径0.3毫米的Habib射频消融导管在纤细的穿刺针的帮助下，穿刺进入胰腺肿瘤不同部位，进行射频消融治疗。  毫米直径——肿瘤消融治疗器械最“苗条”的导管，仅仅相当于3、4根头发丝的粗细！

Pathology：维生素A或可有效改善胰腺癌的化疗效果

在英国，每年约有8800人被诊断出胰腺癌。胰腺癌是美国最为罪名的癌症，存活率不足3%。单纯化疗和放疗往往无法治愈，手术切除则是最佳的治疗方法，大部分患者在癌细胞已发生转移时才确诊。因此，亟需一种不同的不同的治疗方法来更有效地治疗胰腺癌。原始出处：Vitamin A may help improve pancreatic cancer chemotherapy.AAAS and EurekAlert

Nat Genet：林东昕院士揭示抑制胰腺癌lincRNA---LINC00673作用机制

中国医学科学院北京协和医学院的研究人员在新研究中揭示，在基因间长链非编码RNA (lincRNA) LINC00673中的一个胰腺癌风险变异为miR-1231构建了一个结合位点，干扰了PTPN11降解。这一重要的研究发现发布在5月23日的《自然遗传学》（Nature Genetics）杂志上。中国医学科学院的林东昕（Dongxin Lin）院士以及吴晨（Ch

Cell：胰腺癌的潜在治疗靶标Lin28b被发现

-在一项新的研究中，来自美国麻省总医院（MGH）等机构的研究人员鉴定出一种最为常见的被称作胰腺导管腺癌（pancreatic ductal adenocarcinoma, PDAC）的胰腺癌类型的首个潜在的分子治疗靶标。除了发现在大约30%的PDAC病例中肿瘤抑制蛋白SIRT6失活之外，研究人员还鉴定出SIRT6抑制PDAC发展的精确分子机制，这一机制不同于它抑制结直肠癌的方式。相关研究结果于

Cell：首次鉴定出胰腺癌的潜在治疗靶标

发现肿瘤抑制蛋白SIRT6在约30%的胰腺导管腺癌(PDAC)中失活，该研究小组确定了SIRT6抑制PDAC形成的确切信号通路，这一机制不同于它抑制大肠癌的途径。该研究论文在线发布在《细胞》（Cell）杂志上。

Lancet：胰腺癌术后辅助化疗，S-1不劣于吉西他滨

虽然吉西他滨辅助化疗是治疗切除胰腺癌患者的标准治疗方法，对于晚期疾病S-1已经显示出非劣效于吉西他滨的特性。该研究的目的是调查对于整体存活率方面，S-1对于吉西他滨作为辅助化疗胰腺癌的非劣效性。原始出处：Katsuhiko Uesaka,Narikazu Boku,Akira Fukutomi,et al.Adjuvant chemotherapy of S-1 versus gemcitabin

Baidu
map
Baidu
map
Baidu
map